August 22, 2024 | 11:00AM EST | 3:00PM UTC In this webinar, you will: Explore how using a proteomics approach with REpAb® de novo sequencing accesses a larger diversity of antibodies, and enhances antibody discovery workflows. Case study on de novo sequencing functional and neutralizing antibodies directly from the serum of a Human [...]
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Written by: Genya Gorshtein, MSc Published: June 10, 2024 Contents Introduction Alanine Scanning Mutagenesis Epitope Mapping HDX-MS Epitope Mapping Antibody Epitope Mapping Services Introduction Epitope mapping elucidates the antibody function by identifying specific binding sites on the antigen that interact with the antibody. Alanine [...]
In this webinar, you will learn: How AI and HDX-MS are applied in screening, epitope mapping, and selecting neutralizing antibodies against SARS-Cov-2. The predictive capabilities of AI computational modeling and its validation and refinement by high-resolution HDX-MS. How the integration of AI with HDX-MS informs antibody characterization for the accelerated development of therapeutic [...]
Written by: Genya Gorshtein, MSc Published: May 29, 2024 Contents Introduction What is Epitope Binning Value of Epitope Binning in Early Discovery Stages Epitope Binning with SPR on Biacore 1K Introduction An epitope is an inherent property of an antibody that cannot be altered [...]
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Written by: Jenna Kerry, MSc Published: May 1, 2024 Contents What are Autoantibodies? How are Autoantibodies Produced? How do Autoantibodies Become Pathogenic? Triggers for Pathogenic Autoantibodies Autoantibodies in Diagnosis and Treatment Autoantigen Discovery and Characterization Gaining Insight into Autoantibodies What Are Autoantibodies? Autoantibodies are a [...]
Written by: Genya Gorshtein, MSc Published: April 19, 2024 Contents Introduction Bispecifics and Multispecific Antibody Formats Mechanism of Action of Bispecific Antibodies Bispecific and Multispecific Development with Rapid Novor Introduction The complex nature of diseases often limits the therapeutic efficacy of monovalent antibodies. To [...]
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Written by: Genya Gorshtein, MSc Published: April 3, 2024 Contents Introduction Membrane Proteins are Difficult Antigens Strategies for Utilizing Membrane Proteins as Antigens in Antibody Discovery In Vivo Antibody Discovery Using Mass Spectrometry Introduction Membrane proteins orchestrate a wide range of cellular functions, such [...]
Written by: Genya Gorshtein, MSc Published: February 17, 2023 Contents The Drug Development Pathway Target Discovery and Validation Antibody Discovery Characterization and Lead Selection Engineering and Optimization Candidate Selection Therapeutic Antibody Discovery with Rapid Novor The Drug Development Pathway The four phases in the drug [...]
Written by: Genya Gorshtein, MSc Published: November 1, 2022 Contents Introduction Approaches for Engineering Antibody Therapeutics Driving Antibody Engineering with Next Generation Protein Sequencing and Proteomics Introduction Antibody engineering encompasses various development, production strategies, and modification techniques to improve the biological properties of monoclonal antibodies (mAbs) [...]
Written by: Genya Gorshtein, MSc Published: November 25, 2022 Contents Introduction General PROTAC Structure and Function Antibody-Conjugated PROTACs Developing AbPROTACs with De Novo Antibody Sequencing and Proteomics Introduction Small-molecule drug development is aimed at inhibiting disease-promoting protein function through occupancy-driven protein inhibition. A major caveat of [...]
De novo protein sequencing provided the research team with insurance by securing the complete amino acid sequence of a therapeutic mAb candidate for ADAD. This mass spectrometry-based protein sequencing technique can be used to obtain the sequence information of any antibody or protein for biomarker discovery, characterization, and validation. Access to this structural information only broadens our understanding of disease pathogenesis and fosters the development of innovative therapeutic or preventative treatments.
Written by: Genya Gorshtein, MSc Published: September 14, 2022 Contents Introduction ADCs as Novel Anti-Cancer Chemotherapeutics Key Components of ADCs Future Generation of ADCs De Novo Protein Sequencing Applications in ADC Development Introduction An antibody-drug conjugate (ADC) is a monoclonal antibody (mAb) with a covalently attached [...]
Written by: Genya Gorshtein, MSc Published: August 18, 2022 Contents Introduction How are Polyclonal Antibodies Produced? Applications of Polyclonal Antibodies Challenges of Polyclonal Antibodies De Novo Polyclonal Antibody Sequencing Introduction Polyclonal antibodies (pAbs) are a heterogeneous mix of antibodies derived from B cells in the [...]
Written by: Vanessa Yoon Calvelo, PhD Published: August 3, 2022 Contents What are Biosimilar Drugs? Why are Biosimilars Being Developed? Biosimilars are not the Equivalent of Generics Biosimilar Development Biosimilar Monoclonal Antibodies De Novo Protein Sequencing Solutions in Biosimilar Development What are Biosimilar Drugs? Biosimilar drugs, [...]
As nearly all individuals have pre-existing immunity to influenza viruses, influenza-specific memory B cells will likely be recalled upon COBRA HA vaccination. By comparing the antibody response towards specific wild-type influenza strains and COBRA antigens, we can begin to understand the potential for COBRA-based vaccines to be used in the clinic.
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Research Challenges in Veterinary Medicine Since 2006, the One Health Initiative (OHI)’s goal has been to demonstrate the inextricable link between humans, animals, and the environment.
Since 2006, the One Health Initiative (OHI)’s goal has been to demonstrate the inextricable link between humans, animals, and the environment. Certainly, the current global pandemic is a great testament to the ties between climate change, humans, and animals that OHI has been working to highlight. The rise of other zoonotic diseases (e.g., Hendra, and Nipah viruses) not only directly affect humans through disease transmission but may also result in deep impacts to the food supply
The transition from polyclonal antibody drugs to a more targeted monoclonal approach was made possible through a series of scientific and technological advancements; the most notable of which is the hybridoma technique developed by Köhler and Milstein, which allowed the generation of pure antibodies at scale.
Bispecific therapeutics are monoclonal antibodies that carry a specific antigen-binding capability on each arm. Bispecifics are thus capable of having two specificities that can either double the binding affinity of the antibody toward the same antigen (increased avidity), or can now bind to two targets. Bispecifics are most often described as two types: trispecifics and bispecific T-cell engaged antibodies (BiTE).
Over the past several years Rapid Novor has been developing the world’s best antibody protein sequencing platform, sequencing over 2700 monoclonal antibodies and proteins. In 2020, they unveiled their most advanced technology to date - REpAb® polyclonal antibody sequencing. The platform combines the world’s best protein sequencing technology and NGS to comprehensively mine the antigen-specific antibody repertoire present in rabbit and human patient samples. By leveraging the platform, teams can build robust antibody assays and therapeutic leads derived from patients’ blood.
Mouse monoclonal antibodies (mAbs) are highly attractive for manipulation for therapeutic applications as their manufacturing is relatively easy and well-established compared to mAbs derived from larger animal models. However, they also pose several challenges which limit their use as therapeutic agents.
Our team has perfected the art of monoclonal antibody sequencing and is now ready to demonstrate our ability to sequence mAbs from polyclonal mixtures. In this talk, Anthony will walk through our new polyclonal sequencing platform that uses both proteomics and genomics to sequence the most abundant antibodies found in polyclonal sera.